Article Information
History
- November 12, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Christopher Humphries1,
- Ellise Clarke2,
- Michael Eddleston1,
- Marianne Gillings3,
- Sîan Irvine4,
- Liza Keating5,
- Anna Miell2,
- Lynsey Milne4,
- Laura Muir3,
- Rachel O’Brien2,
- Katherine Oatey4,
- Rajendra Raman6,
- Ruben Thanacoody3,
- Sharon Tuck4,
- Christopher J Weir4,
- David M Wood5,
- James W Dear1,* and
- HiSNAP Trial Investigators
- 1Centre for Cardiovascular Science, University of Edinburgh, The Queen’s Medical Research Institute, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK
- 2Emergency Medicine Research Group Edinburgh, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh, EH16 4SA, UK
- 3HiSNAP Trial Steering Committee, Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, 5-7 Little France Road, Edinburgh, EH16 4UX, UK
- 4Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, 5-7 Little France Road, Edinburgh, EH16 4UX, UK
- 5HiSNAP Data Monitoring Committee, Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, 5-7 Little France Road, Edinburgh, EH16 4UX, UK
- 6Victoria Hospital, Hayfield Road, Kirkcaldy, KY2 5AH
- ↵* Corresponding author; email: james.dear{at}ed.ac.uk
Posted November 12, 2024.
Study protocol: HiSNAP trial – a multi-centre, randomised, open label, blinded end-point, safety and efficacy trial of conventional (300mg/kg) versus higher doses of acetylcysteine (450mg/kg and 600mg/kg) in patients with paracetamol overdose in the United Kingdom
